Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1938 studies found for:    Farber's Disease
Show Display Options
RSS Create an RSS feed from your search for:
Farber's Disease
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Biomarker for Farber Disease
Conditions: Farber's Lipogranulomatosis;   Ceramidase Deficiency;   Farber Disease;   Acid Ceramidase Deficiency;   AC Deficiency
Intervention:
2 Completed Mantle Irradiation for Hodgkin's Disease
Condition: Hodgkin's Disease
Intervention: Procedure: Mantle irradiation
3 Recruiting A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host-disease
Interventions: Procedure: Extracorporeal Photopheresis (ECP);   Drug: Interleukin-2
4 Active, not recruiting Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation
Condition: Hodgkin's Disease
Intervention: Procedure: Echo/Stress Echo
5 Recruiting Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Condition: Graft Versus Host Disease
Interventions: Drug: Natalizumab;   Drug: Methylprednisolone
6 Completed Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease
Conditions: Breast Cancer;   Hodgkin's Disease
Interventions: Procedure: breast MRI;   Procedure: Mammogram
7 Active, not recruiting
Has Results
Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease
Condition: Lung Cancer
Intervention: Procedure: chest computed tomography scan
8 Recruiting Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Versus Graft Host Disease
Intervention: Drug: Interleukin-2
9 Not yet recruiting A Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Graft vs. Host Disease
Interventions: Drug: Obinutuzumab;   Drug: Placebo
10 Completed Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: Rituximab
11 Completed Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
Conditions: Hodgkin's Disease;   Breast Cancer
Intervention: Drug: Tamoxifen
12 Not yet recruiting Phase II Protocol Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
Condition: Bone Cancer
Interventions: Drug: Stereotactic Body Radiation Therapy (SBRT);   Device: Stereotactic Linear Accelerator
13 Active, not recruiting
Has Results
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
Condition: Graft Versus Host Disease
Intervention: Drug: Interleukin-2
14 Completed
Has Results
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
Condition: Chronic Graft Versus Host Disease
Interventions: Drug: bortezomib;   Drug: Prednisone
15 Recruiting Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Conditions: Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions: Other: Treg-enriched infusion;   Drug: Interleukin-2
16 Completed
Has Results
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Condition: Hematologic Malignancies
Interventions: Drug: Bortezomib (Velcade);   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: blood stem cell transplantation
17 Active, not recruiting
Has Results
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Interleukin-2
18 Terminated
Has Results
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
Condition: Graft-vs-Host Disease
Interventions: Drug: Sirolimus;   Drug: Mycophenolate mofetil;   Drug: Bortezomib
19 Completed Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
Conditions: Graft Versus Host Disease;   Hematologic Malignancies
Interventions: Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Stem Cell Transplantation
20 Terminated
Has Results
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Alefacept

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.